Literature DB >> 8642041

Lessons from the p53 mutant mouse.

T Jacks1.   

Abstract

The use of the mouse as a model organism in cancer research has a long and productive history, from the earliest studies of chemical carcinogenesis to the recent advances in gene targeting. Many of the basic principles of tumorigenesis have been formed in whole or in part through the study of tumor development in the mouse. Over the past decade, the major experimental approach has been to generate cancer-prone strains, either through transgenic technologies or, more recently, gene targeting. Here, I will review the state of the field of gene targeting of tumor-suppressor genes and concentrate on the p53 mutant strains and the lessons learned from the p53 mutant mouse.

Entities:  

Mesh:

Year:  1996        PMID: 8642041     DOI: 10.1007/bf01220798

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  78 in total

Review 1.  The neurofibromatosis type 1 gene.

Authors:  D Viskochil; R White; R Cawthon
Journal:  Annu Rev Neurosci       Date:  1993       Impact factor: 12.449

2.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

3.  WT-1 is required for early kidney development.

Authors:  J A Kreidberg; H Sariola; J M Loring; M Maeda; J Pelletier; D Housman; R Jaenisch
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

4.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

Authors:  T Miyashita; J C Reed
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

5.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

6.  Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene.

Authors:  C A Purdie; D J Harrison; A Peter; L Dobbie; S White; S E Howie; D M Salter; C C Bird; A H Wyllie; M L Hooper
Journal:  Oncogene       Date:  1994-02       Impact factor: 9.867

7.  Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.

Authors:  T Jacks; T S Shih; E M Schmitt; R T Bronson; A Bernards; R A Weinberg
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

8.  Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues.

Authors:  C I Brannan; A S Perkins; K S Vogel; N Ratner; M L Nordlund; S W Reid; A M Buchberg; N A Jenkins; L F Parada; N G Copeland
Journal:  Genes Dev       Date:  1994-05-01       Impact factor: 11.361

9.  Cooperative tumorigenic effects of germline mutations in Rb and p53.

Authors:  B O Williams; L Remington; D M Albert; S Mukai; R T Bronson; T Jacks
Journal:  Nat Genet       Date:  1994-08       Impact factor: 38.330

Review 10.  Mutations in the APC gene and their implications for protein structure and function.

Authors:  P Polakis
Journal:  Curr Opin Genet Dev       Date:  1995-02       Impact factor: 5.578

View more
  8 in total

1.  Role of p14(ARF) in replicative and induced senescence of human fibroblasts.

Authors:  W Wei; R M Hemmer; J M Sedivy
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

Review 2.  Can ends justify the means?: telomeres and the mechanisms of replicative senescence and immortalization in mammalian cells.

Authors:  J M Sedivy
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

3.  The MutSβ complex is a modulator of p53-driven tumorigenesis through its functions in both DNA double-strand break repair and mismatch repair.

Authors:  J M M van Oers; Y Edwards; R Chahwan; W Zhang; C Smith; X Pechuan; S Schaetzlein; B Jin; Y Wang; A Bergman; M D Scharff; W Edelmann
Journal:  Oncogene       Date:  2013-09-09       Impact factor: 9.867

4.  Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53.

Authors:  H Nozawa; E Oda; K Nakao; M Ishihara; S Ueda; T Yokochi; K Ogasawara; Y Nakatsuru; S Shimizu; Y Ohira; K Hioki; S Aizawa; T Ishikawa; M Katsuki; T Muto; T Taniguchi; N Tanaka
Journal:  Genes Dev       Date:  1999-05-15       Impact factor: 11.361

5.  Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits Ras-induced anchorage-independent growth in telomerase-immortalized human fibroblasts.

Authors:  Wenyi Wei; Wendy A Jobling; Wen Chen; William C Hahn; John M Sedivy
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

6.  Lactation-induced WAP-SV40 Tag transgene expression in C57BL/6J mice leads to mammary carcinoma.

Authors:  M R Hüsler; K A Kotopoulis; J P Sundberg; B J Tennent; S V Kunig; B B Knowles
Journal:  Transgenic Res       Date:  1998-07       Impact factor: 2.788

7.  Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer Gene.

Authors:  Sarah Gramling; David Reisman
Journal:  Lett Drug Des Discov       Date:  2011-01-01       Impact factor: 1.150

Review 8.  Tumor suppressive pathways in the control of neurogenesis.

Authors:  Stefano Bartesaghi; Paolo Salomoni
Journal:  Cell Mol Life Sci       Date:  2012-07-17       Impact factor: 9.261

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.